Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: R-Evolution Group EEIG
Street 1: via Napoli, 188
Street 2:
City: Santo Spirito BARI
Post Code: 70127
Country: Italy
Phone: +39 347 3631971
Organization Email:
Web Site:
Other Online Presence:

Focal Point Contact Information

Salutation: Mr
First Name: Dario
Last Name: Scaramuzzi
Title: Director

Alternate Focal Point Contact Information

Salutation: Mr
First Name: Martin
Last Name: Mayrleitner

General Information

Board Constituency: Communities
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Partnership
Organization Type - Secondary: International Partnership
Organization Description:
Our mission:
Today's social environment is asking for a change, and the same is occurring in the clinical research & development field.
Our mission is to create alliances based on human values and an innovative vision of life, work, and relationships.
We believe in a new paradigm, Research and Development driven by Social Responsibility and Sustainability, based on:
• developing relationships with public and private partners aimed at mutual growth and enrichment
• linking the interests of Stakeholders with those of Researchers, Networks, Small & Medium Enterprises, Start-Ups, Investors, Patients' Associations, Academia, Institutions, International Organizations and Funding agencies, thus creating synergistic connections
• finding sustainable solutions for the R&D challenges of today, and tomorrow.

Our vision:
We believe in a change of work paradigm, based on a dynamic balance between professional, human and social values. We work on achievement goals, but we also are looking for a social and human transformation that creates deep satisfaction and fulfillment.
We exit from power struggles, control and individualisms, in order to create a high potential partnerships.
We are looking for co-developing rather than services providing collaborations.
We are the first Group of Experts in Clinical R&D granted by the European Union of the Transnational Consortium legal status: our value is uniqueness rather than competitiveness.
We are Clinical Research Experts who are co-working, who believe in the potential of a Group, co-creators of the organization, so levels of devotion and engagement are high.
We create this Group not for a need but for a challenge, with this aim we have chosen each other, therefore cohesion and proactiveness is the characteristic of our team.
We strongly believe in the capacity building for the creation of an environment that can trigger virtuous paths promoting sustainable research & development.
The Group manage, but not limited to, the following aspects of research &
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Research and Development

Other Organization Information

Total number of staff in your organization: 11 - 25
Number of full-time staff who are directly involved with TB: 0
Number of part-time staff who are directly involved with TB: 1 - 5
Number of volunteers who are directly involved with TB: 1 - 5
How did you hear about the Stop TB Partnership: Internet search
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Information on developments within the TB world
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
Our organization has a deep knowledge and great experience in clinical research and development of therapies. In addition to this its legal status of transnational consortium that sets able of partnership very efficient for clinical research in the field of TB, especially in field management of clinical trials for new therapies.

Geographical Reach

Which country is your headquarters located in: Italy
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Republic of Moldova
Sierra Leone


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

Drug-Resistant TB:
Please see below, in the "New TB Vaccines" comment field

New Diagnostics:
Please see below, in the "New TB Vaccines" comment field

New TB Drugs:
Please see below, in the "New TB Vaccines" comment field

New TB Vaccines:
R-Evolution Group is an organization of clinical research experts with a deep knowledge and field experience in the management of GCP/FDA clinical trials of new therapies, vaccines, and diagnostics, covering more than 23 countries.
We provide all kind of support needed to manage clinical trials in the countries with highest incidence of tuberculosis, MDR-tuberculosis, and XDR-tuberculosis, especially in Europe, Eastern Europe and Africa.
R-Evolution Group feeds the capacity building for the creation of an environment that can trigger virtuous paths promoting highest quality standards tuberculosis clinical trials.
We would like to strengthen partnerships with private and public stakeholders involved in the TB, MDR-TB, and XDR-TB clinical research, linking the interests of Stakeholders, Researchers, Networks, Small & Medium Enterprises, Start-Ups, Spin-Off, Investors, Patients' Associations, Advocates, Academia, Institutions, International Organizations and Funding Agencies, thus creating synergistic connections to promote tuberculosis clinical research.
On these basis, we are also interested to explore the use of the potential of the same organization and skills just established in Sierra Leone, Liberia, and Guinea for the vaccine clinical trials against Ebola also for the TB / MDR-TB / XDR-TB clinical trials. As an example, the STRIVE is the trial of a vaccine against Ebola, involving in Sierra Leone 7 clinics in which 8650 people were enrolled in few weeks, then vaccinated and followed-up. The trial was organized in adherence to the highest global quality standards and in strictly compliance with international regulations. The study strengthened the existing research capacity of institutions in Sierra Leone by providing training (e.g.trainings on Good Clinical Practice - GCP, Human Subjects Protection-HSP, Good Documenting Practice-GDP and Good Clinical Data Management Practices - GCDMP) and research experience to 450 of Sierra Leone staff, which can be used for future trials. Infrastructure has been expanded, including renovating existing structures and building new ones to be able to enrol, vaccinate, and follow-up participants, handle data management, and store the investigational product.


Declaration of interests:
No conflicts of interest were delacred.

Application date: January 15, 2016
Last updated: March 31, 2016